Autosomal Dominant Hypocalcemia (Hypoparathyroidism) Types 1 and 2
Roszko, Kelly L.
MetadataShow full item record
CitationRoszko, Kelly L., Ruiye D. Bi, and Michael Mannstadt. 2016. “Autosomal Dominant Hypocalcemia (Hypoparathyroidism) Types 1 and 2.” Frontiers in Physiology 7 (1): 458. doi:10.3389/fphys.2016.00458. http://dx.doi.org/10.3389/fphys.2016.00458.
AbstractExtracellular calcium is essential for life and its concentration in the blood is maintained within a narrow range. This is achieved by a feedback loop that receives input from the calcium-sensing receptor (CASR), expressed on the surface of parathyroid cells. In response to low ionized calcium, the parathyroids increase secretion of parathyroid hormone (PTH) which increases serum calcium. The CASR is also highly expressed in the kidneys, where it regulates the reabsorption of calcium from the primary filtrate. Autosomal dominant hypocalcemia (ADH) type 1 is caused by heterozygous activating mutations in the CASR which increase the sensitivity of the CASR to extracellular ionized calcium. Consequently, PTH synthesis and secretion are suppressed at normal ionized calcium concentrations. Patients present with hypocalcemia, hyperphosphatemia, low magnesium levels, and low or low-normal levels of PTH. Urinary calcium excretion is typically increased due to the decrease in circulating PTH concentrations and by the activation of the renal tubular CASR. Therapeutic attempts using CASR antagonists (calcilytics) to treat ADH are currently under investigation. Recently, heterozygous mutations in the alpha subunit of the G protein G11 (Gα11) have been identified in patients with ADH, and this has been classified as ADH type 2. ADH2 mutations lead to a gain-of-function of Gα11, a key mediator of CASR signaling. Therefore, the mechanism of hypocalcemia appears similar to that of activating mutations in the CASR, namely an increase in the sensitivity of parathyroid cells to extracellular ionized calcium. Studies of activating mutations in the CASR and gain-of-function mutations in Gα11 can help define new drug targets and improve medical management of patients with ADH types 1 and 2.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29626003
- HMS Scholarly Articles 
Contact administrator regarding this item (to report mistakes or request changes)